Flowmail

Flowmail

Flowmail

Flowmail is the easiest way to create beautiful mobile-first newsletters. Sign up today on our site
Founded
2013
Follow us
Alexa global traffic share
Twitter followers
Team Size
2
Employees
Pulse 2.0

Editas Medicine (EDIT) Stock Price: Why It Increased 7.77% Today

Pulse 2.0

Editas Medicine Stock (EDIT): Why The Price Fell Today

Pulse 2.0

Editas Medicine Stock (EDIT): Why The Price Jumped Today

Xconomy

Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic

$50,000,000 Venture capital (Series A)
FinSMEs

Rome Therapeutics Raises $50M in Series A Financing

$52,000,000 Venture capital (Series A)
FinSMEs

SwanBio Therapeutics Raises $52M in Series A

$60,000,000 Venture capital (Series A)
FinSMEs

Affinia Therapeutics Raises $60M in Series A Financing

$105,000,000 Venture capital (Series B)
FinSMEs

Akouos Raises $105M in Series B Financing

$105,000,000 Venture capital (Series B)
Pulse 2.0

Precision Genetic Medicine Company Akouos Secures $105 Million In Funding

the home of AI info

Comparing of Minerva Neurosciences Inc. (NERV) and Magenta Therapeutics Inc. (NASDAQ:MGTA)

MedCity News

Editas Medicine CEO steps down as company moves into product development stage

FinSMEs

Alexion To Acquire Syntimmune, for Up To $1.2 Billion

Health
$50,000,000 Venture capital (Series A)
FinSMEs

Precision Genetic Medicine Company Akouos Raises $50M in Series A

Science Funding Health
$100,000,000 IPO
PE HUB

Magenta Therapeutics starts trading on the NASDAQ

Stock markets Health
$52,000,000 Venture capital (Series C)
Venture Funding News , PE HUB

Magenta Therapeutics Secures $52M in Series C

FinSMEs

Magenta Therapeutics Secures $52M in Series C Financing

Funding Health
PE HUB

| Apple Tree-backed Syntimmune appoints president and CEO

Strategy Health
PE HUB

VC-backed Spero Therapeutics sets IPO pricing terms

Stock markets Funding
PE HUB

VC-backed Spero Therapeutics files for IPO

Stock markets Health Funding
$20,000,000 Venture capital (Series D)
prnewswire

Sebacia Announces $36 Million Equity and Debt Financing to Advance Breakthrough In-Office Procedure for Acne